RecruitingPhase 2NCT07182526

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients

Sponsor

Al-Mustansiriyah University

Enrollment

150 participants

Start Date

Sep 20, 2025

Study Type

INTERVENTIONAL

Conditions

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Summary

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

• Newly diagnosed patients should be at reproductive aged from 18-40 years.
Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
Oligomenorrhea with inter-menstrual intervals longer than 35 days.
Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).
Normal PRL levels.

Exclusion Criteria4

• Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes.
Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).
Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.
Pregnant women.